Lecalpin

Lercanidipine Hydrochloride, the active ingredient in Lecalpin, is a calcium channel blocker presented as an oral dosage form for oral use. It treats hypertension in adult patients by lowering systemic blood pressure.

GNH USA supplies Lecalpin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecalpin, a calcium channel blocker, is employed in the management of elevated arterial pressure.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Lecalpin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Nausea

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Hepatic dysfunction - Allergic reactions including rash - Angioedema - Cardiac arrhythmias

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Elderly patients: start at the lowest effective dose and monitor closely. - Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects. - CYP3A4 inhibitors: avoid strong inhibitors that may increase drug exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lecalpin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels. - Grapefruit juice: can increase drug exposure and risk of hypotension. - Other potent antihypertensives: may cause additive blood‑pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: observe for excessive heart‑rate slowing. - NSAIDs: may blunt antihypertensive response. - Lithium: monitor lithium levels for potential toxicity.